Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
Puma Biotechnology, Inc. (PBYI) BCG Matrix Analysis
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Puma Biotechnology Inc Company Profile - GlobalData
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top | Nasdaq
Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC
Puma Biotechnology
Puma Biotechnology, Inc. - SEC Filings - Annual Reports & Proxies
Puma Biotech Surges, Defying Yellen
Puma Biotechnology Inc (PBYI) Stock Message Board | InvestorsHub
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology begins Phase II trial of lung cancer drug
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity | Market Exclusive
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
EX-99.1
Puma Biotechnology unveils Phase II breast cancer trial design
Puma Biotech anti-HER2 breast cancer drug approved in China - BioTuesdays
Puma Biotechnology Inc (PBYI) Reports Positive Net Income for Q4 and Full Year 2023
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Is This Low-Priced Biotech Stock a Hidden Gem? - TheStreet's Real Money Pro
Puma Biotechnology: Profitable, Troubled, But Worth A Good Look (NASDAQ:PBYI) | Seeking Alpha
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now | Nasdaq
